Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04760769 · ClinicalTrials.gov registry record · Phase 3
Open-label Trial in Parkinson's Disease (PD)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 992
- Enrollment target
NCT04760769: Completed Phase 3 study, sponsored by AbbVie.
NCT04760769 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 992 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04760769, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 992 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Primary Outcome
An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, Vital Signs, Physical and Neurological evaluations and E
Interventions
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 992 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 3 |
What the finished NCT04760769 record still lists
NCT04760769 is an interventional study that assigns participants to a tested intervention. The registered 992 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 1 intervention - of which Tavapadon is the first listed.
NCT04760769 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04760769 about?
NCT04760769 is a clinical study titled "Open-label Trial in Parkinson's Disease (PD)". The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
What is the current status of trial NCT04760769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 992 participants. The study started on 2021-02-24. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT04760769?
The interventions under investigation include: Tavapadon (DRUG).
Who is sponsoring clinical trial NCT04760769?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04760769's enrollment target sits among peer trials
992 314th of 2000 higher than 1,686 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI